365 related articles for article (PubMed ID: 29936228)
41. Discovery of Novel Pyridazine-Based Cyclooxygenase-2 Inhibitors with a Promising Gastric Safety Profile.
Khan A; Diwan A; Thabet HK; Imran M; Bakht MA
Molecules; 2020 Apr; 25(9):. PubMed ID: 32344801
[TBL] [Abstract][Full Text] [Related]
42. Fluorescent indomethacin-dansyl conjugates utilize the membrane-binding domain of cyclooxygenase-2 to block the opening to the active site.
Xu S; Uddin MJ; Banerjee S; Duggan K; Musee J; Kiefer JR; Ghebreselasie K; Rouzer CA; Marnett LJ
J Biol Chem; 2019 May; 294(22):8690-8698. PubMed ID: 31000626
[TBL] [Abstract][Full Text] [Related]
43. Design, synthesis, and biological evaluation of substituted hydrazone and pyrazole derivatives as selective COX-2 inhibitors: Molecular docking study.
El-Sayed MA; Abdel-Aziz NI; Abdel-Aziz AA; El-Azab AS; Asiri YA; Eltahir KE
Bioorg Med Chem; 2011 Jun; 19(11):3416-24. PubMed ID: 21570309
[TBL] [Abstract][Full Text] [Related]
44. Virtual screening, pharmacokinetics, molecular dynamics and binding free energy analysis for small natural molecules against cyclin-dependent kinase 5 for Alzheimer's disease.
Shukla R; Singh TR
J Biomol Struct Dyn; 2020 Jan; 38(1):248-262. PubMed ID: 30688165
[TBL] [Abstract][Full Text] [Related]
45. The discovery of new acetylcholinesterase inhibitors derived from pharmacophore modeling, virtual screening, docking simulation and bioassays.
Zhang Y; Zhang S; Xu G; Yan H; Pu Y; Zuo Z
Mol Biosyst; 2016 Nov; 12(12):3734-3742. PubMed ID: 27801451
[TBL] [Abstract][Full Text] [Related]
46. Interactions of selected indole derivatives with COX-2 and their in silico structure modifications towards the development of novel NSAIDs.
Dileep KV; Remya C; Tintu I; Sadasivan C
J Biomol Struct Dyn; 2014; 32(11):1855-63. PubMed ID: 24053423
[TBL] [Abstract][Full Text] [Related]
47. Pharmacoinformatics exploration of polyphenol oxidases leading to novel inhibitors by virtual screening and molecular dynamic simulation study.
Hassan M; Abbas Q; Ashraf Z; Moustafa AA; Seo SY
Comput Biol Chem; 2017 Jun; 68():131-142. PubMed ID: 28340400
[TBL] [Abstract][Full Text] [Related]
48. Structure-based design of hERG-neutral antihypertensive oxazalone and imidazolone derivatives.
Aksoydan B; Kantarcioglu I; Erol I; Salmas RE; Durdagi S
J Mol Graph Model; 2018 Jan; 79():103-117. PubMed ID: 29156380
[TBL] [Abstract][Full Text] [Related]
49. Discovery of selective dengue virus inhibitors using combination of molecular fingerprint-based virtual screening protocols, structure-based pharmacophore model development, molecular dynamics simulations and in vitro studies.
Mirza SB; Lee RCH; Chu JJH; Salmas RE; Mavromoustakos T; Durdagi S
J Mol Graph Model; 2018 Jan; 79():88-102. PubMed ID: 29156382
[TBL] [Abstract][Full Text] [Related]
50. Antiproliferative Benzoindazolequinones as Potential Cyclooxygenase-2 Inhibitors.
Molinari A; Oliva A; Arismendi-Macuer M; Guzmán L; Acevedo W; Aguayo D; Vinet R; San Feliciano A
Molecules; 2019 Jun; 24(12):. PubMed ID: 31216654
[TBL] [Abstract][Full Text] [Related]
51. Identification of novel PI3Kδ inhibitors by docking, ADMET prediction and molecular dynamics simulations.
Liu YY; Feng XY; Jia WQ; Jing Z; Xu WR; Cheng XC
Comput Biol Chem; 2019 Feb; 78():190-204. PubMed ID: 30557817
[TBL] [Abstract][Full Text] [Related]
52. Discovery of Camptothecin Based Topoisomerase I Inhibitors: Identification Using an Atom Based 3D-QSAR, Pharmacophore Modeling, Virtual Screening and Molecular Docking Approach.
Dev S; Dhaneshwar SR; Mathew B
Comb Chem High Throughput Screen; 2016; 19(9):752-763. PubMed ID: 27515040
[TBL] [Abstract][Full Text] [Related]
53. Novel virtual lead identification in the discovery of hematopoietic cell kinase (HCK) inhibitors: application of 3D QSAR and molecular dynamics simulation.
Bavi R; Kumar R; Rampogu S; Kim Y; Kwon YJ; Park SJ; Lee KW
J Recept Signal Transduct Res; 2017 Jun; 37(3):224-238. PubMed ID: 27485399
[TBL] [Abstract][Full Text] [Related]
54. Potential inhibitors for FKBP51: an
Barge S; Jade D; Ayyamperumal S; Manna P; Borah J; Nanjan CMJ; Nanjan MJ; Talukdar NC
J Biomol Struct Dyn; 2022; 40(24):13799-13811. PubMed ID: 34709133
[TBL] [Abstract][Full Text] [Related]
55. In silico assessment of new progesterone receptor inhibitors using molecular dynamics: a new insight into breast cancer treatment.
Zarezade V; Abolghasemi M; Rahim F; Veisi A; Behbahani M
J Mol Model; 2018 Nov; 24(12):337. PubMed ID: 30415281
[TBL] [Abstract][Full Text] [Related]
56. Identification of novel inhibitor of protein tyrosine phosphatases delta: structure-based pharmacophore modeling, virtual screening, flexible docking, molecular dynamics simulation, and post-molecular dynamics analysis.
Ma YC; Yang B; Wang X; Zhou L; Li WY; Liu WS; Lu XH; Zheng ZH; Ma Y; Wang RL
J Biomol Struct Dyn; 2020 Sep; 38(15):4432-4448. PubMed ID: 31625456
[TBL] [Abstract][Full Text] [Related]
57. Ligand- and structure-based in silico studies to identify kinesin spindle protein (KSP) inhibitors as potential anticancer agents.
Balakumar C; Ramesh M; Tham CL; Khathi SP; Kozielski F; Srinivasulu C; Hampannavar GA; Sayyad N; Soliman ME; Karpoormath R
J Biomol Struct Dyn; 2018 Nov; 36(14):3687-3704. PubMed ID: 29064326
[TBL] [Abstract][Full Text] [Related]
58. 3D Pharmacophore-Based Virtual Screening and Docking Approaches toward the Discovery of Novel HPPD Inhibitors.
Fu Y; Sun YN; Yi KH; Li MQ; Cao HF; Li JZ; Ye F
Molecules; 2017 Jun; 22(6):. PubMed ID: 28598377
[No Abstract] [Full Text] [Related]
59. Rational approach to identify newer caspase-1 inhibitors using pharmacophore based virtual screening, docking and molecular dynamic simulation studies.
Patel S; Modi P; Chhabria M
J Mol Graph Model; 2018 May; 81():106-115. PubMed ID: 29549805
[TBL] [Abstract][Full Text] [Related]
60. Identification of New KRAS G12D Inhibitors through Computer-Aided Drug Discovery Methods.
Kulkarni AM; Kumar V; Parate S; Lee G; Yoon S; Lee KW
Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163234
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
